T-cell Therapy Market Analysis and Forecast to 2032: By Modality (Research, Commercialized), Therapy Type (CAR T-cell Therapy, T-cell Receptor (TCR)-based, Tumor Infiltrating Lymphocytes (TIL)-based), Indication (Hematologic Malignancies, Solid Tumors, Others), and Region
T-cell therapy is a type of immunotherapy that fights cancer by using specifically engineered T cells, which are part of the immune system. T cells from a patient’s blood are taken and manipulated to develop specific structures on their surface known as chimeric antigen receptors. The new receptors on these T cells enable them to latch onto a specific antigen on the patient’s tumor cells and destroy them when they are reinfused into the patient. T-cell therapy is currently approved by the FDA as the standard of care for certain types of aggressive, relapsed, or refractory non-Hodgkin lymphoma, such as diffuse large B cell lymphoma, primary mediastinal B-cell lymphoma, high-grade B-cell lymphoma, transformed follicular lymphoma, and mantle cell lymphoma.
Key Drivers & Trends
T-cell therapy is a type of immunotherapy that uses T-cells, or white blood cells, to treat cancer and other diseases. T-cells are a key part of the immune system and can recognize and kill cancer cells. T-cell therapy is still in the early stages of development, but it shows promise as a treatment for a variety of cancers, including leukemia, lymphoma, and solid tumors. There are several different types of T-cell therapy, including CAR T-cell therapy, which uses genetically-modified T-cells to target cancer cells, and TCR T-cell therapy, which uses T-cells that have been modified to recognize and destroy specific types of cancer cells. T-cell therapy is still being studied in clinical trials and is not yet available as a treatment for cancer.
The key drivers of the T-cell Therapy market are the increasing incidence of cancer and the rising demand for personalized medicine. The increasing incidence of cancer is due to the aging population and the increasing prevalence of lifestyle diseases. The rising demand for personalized medicine is due to the increasing awareness of the importance of tailored treatment and the need for more effective treatments.
Key Restraints & Challenges
The key restraints and challenges in the T-cell Therapy market are:
1. The high cost of T-cell therapy, which can limit its availability to patients who can afford it.
2. The lack of data on the long-term efficacy and safety of T-cell therapy, which can make it difficult for physicians to make informed decisions about its use.
3. The need for specialized infrastructure and personnel to administer T-cell therapy, which can limit its availability in some settings.
4. The potential for serious side effects with T-cell therapy, which requires close monitoring of patients during and after treatment.
Market Segments
The T-cell Therapy market has been segmented into Therapy Type, Indication, Modality, and Region. Based on the Therapy Type, the T-cell Therapy market is segmented into CAR T-cell Therapy, T-cell Receptor (TCR)-based, and Tumor Infiltrating Lymphocytes (TIL)-based. On the basis of Indication, the market is segmented into Hematologic Malignancies, Solid Tumors, and Others. Based on Modality, the market is bifurcated into Research and Commercialized. Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and the Rest of the World.
Key Players
The T-cell therapy market report includes players such as Amgen (US), Bluebird Bio Inc. (US), Fate Therapeutics (US), Gilead Sciences Inc. (US), Merck KGaA (Germany), Novartis AG (Switzerland), Pfizer Inc. (US), Sorrento Therapeutics (US), TCR² Therapeutics (US) and TScan Therapeutics, Inc. (US).
Table of Contents
Chapter 1. T-cell Therapy Market Overview
1.1. Objectives of the Study
1.2. Market Definition and Research & Scope
1.3. Research Limitations
1.4. Research Methodologies
1.4.1. Secondary Research
1.4.2. Market Size Estimation Technique
1.4.3. Forecasting
1.4.4. Primary Research and Data Validation
Chapter 2. Executive Summary
2.1. Summary
2.2. Key Highlights of the Market
Chapter 3. Premium Insights on the Market
3.1. Market Attractiveness Analysis, By Region
3.2. Market Attractiveness Analysis, By Modality
3.3. Market Attractiveness Analysis, By Therapy Type
3.4. Market Attractiveness Analysis, By Indication
Chapter 4. T-cell Therapy Market Outlook
4.1. T-cell Therapy Market Segmentation
4.2. Market Dynamics
4.2.1. Market Drivers
4.2.1.1. Driver 1
4.2.1.2. Driver 2
4.2.1.3. Driver 3
4.2.2. Market Restraints
4.2.2.1. Restraint 1
4.2.2.2. Restraint 2
4.2.3. Market Opportunities
4.2.3.1. Opportunity 1
4.2.3.2. Opportunity 2
4.3. Porter’s Five Forces Analysis
4.3.1. Threat of New Entrants
4.3.2. Threat of Substitutes
4.3.3. Bargaining Power of Buyers
4.3.4. Bargaining Power of Supplier
4.3.5. Competitive Rivalry
4.4. PESTLE Analysis
4.5. Value Chain Analysis
4.5.1. Raw Material Suppliers
4.5.2. Manufacturers
4.5.3. Wholesalers and/or Retailers
4.6. Impact of COVID-19 on the T-cell Therapy Market
4.7. Impact of the Russia and Ukraine War on the T-cell Therapy Market
Chapter 5. T-cell Therapy Market By Modality
5.1. Market Overview
5.2. Research
5.2.1. Market Size And Forecast, 2022-2032 ($Billion)
5.2.2. Market Size And Forecast, By Region, 2022-2032 ($Billion)
5.3. Commercialized
5.3.1. Market Size And Forecast, 2022-2032 ($Billion)
5.3.2. Market Size And Forecast, By Region, 2022-2032 ($Billion)
Chapter 6. T-cell Therapy Market By Therapy Type
6.1. Market Overview
6.2. CAR T-cell Therapy
6.2.1. Market Size And Forecast, 2022-2032 ($Billion)
6.2.2. Market Size And Forecast, By Region, 2022-2032 ($Billion)
6.3. T-cell Receptor (TCR)-based
6.3.1. Market Size And Forecast, 2022-2032 ($Billion)
6.3.2. Market Size And Forecast, By Region, 2022-2032 ($Billion)
6.4. Tumor Infiltrating Lymphocytes (TIL)-based
6.4.1. Market Size And Forecast, 2022-2032 ($Billion)
6.4.2. Market Size And Forecast, By Region, 2022-2032 ($Billion)
Chapter 7. T-cell Therapy Market By Indication
7.1. Market Overview
7.2. Hematologic Malignancies
7.2.1. Market Size And Forecast, 2022-2032 ($Billion)
7.2.2. Market Size And Forecast, By Region, 2022-2032 ($Billion)
7.3. Solid Tumors
7.3.1. Market Size And Forecast, 2022-2032 ($Billion)
7.3.2. Market Size And Forecast, By Region, 2022-2032 ($Billion)
7.4. Others
7.4.1. Market Size And Forecast, 2022-2032 ($Billion)
7.4.2. Market Size And Forecast, By Region, 2022-2032 ($Billion)
Chapter 8. Multi-Cloud Management Market, By Region
8.1. Overview
8.2. North America
8.2.1. Key Market Trends And Opportunities
8.2.2. North America T-cell Therapy Market Size And Forecast By Modality, 2022-2032, ($Billion)
8.2.3. North America T-cell Therapy Market Size And Forecast By Therapy Type, 2022-2032, ($Billion)
8.2.4. North America T-cell Therapy Market Size And Forecast By Indication, 2022-2032, ($Billion)
8.2.5. North America T-cell Therapy Market Size And Forecast By Country, 2022-2032, ($Billion)
8.2.6. The U.S.
8.2.6.1. The U.S. T-cell Therapy Market Size And Forecast By Modality, 2022-2032, ($Billion)
8.2.6.2. The U.S. T-cell Therapy Market Size And Forecast By Therapy Type, 2022-2032, ($Billion)
8.2.6.3. U.S. T-cell Therapy Market Size And Forecast By Indication, 2022-2032, ($Billion)
8.2.7. Canada
8.2.7.1. Canada T-cell Therapy Market Size And Forecast By Modality, 2022-2032, ($Billion)
8.2.7.2. Canada T-cell Therapy Market Size And Forecast By Therapy Type, 2022-2032, ($Billion)
8.2.7.3. Canada T-cell Therapy Market Size And Forecast By Indication, 2022-2032, ($Billion)
8.2.8. Mexico
8.2.8.1. Mexico T-cell Therapy Market Size And Forecast By Modality, 2022-2032, ($Billion)
8.2.8.2. Mexico T-cell Therapy Market Size And Forecast By Therapy Type, 2022-2032, ($Billion)
8.2.8.3. Mexico T-cell Therapy Market Size And Forecast By Indication, 2022-2032, ($Billion)
8.3. Europe
8.3.1. Key Market Trends And Opportunities
8.3.2. Europe T-cell Therapy Market Size And Forecast By Modality, 2022-2032, ($Billion)
8.3.3. Europe T-cell Therapy Market Size And Forecast By Therapy Type, 2022-2032, ($Billion)
8.3.4. Europe T-cell Therapy Market Size And Forecast By Indication, 2022-2032, ($Billion)
8.3.5. Europe T-cell Therapy Market Size And Forecast By Country, 2022-2032, ($Billion)
8.3.5.1. Germany
8.3.5.2. Germany T-cell Therapy Market Size And Forecast By Modality, 2022-2032, ($Billion)
8.3.5.3. Germany T-cell Therapy Market Size And Forecast By Therapy Type, 2022-2032, ($Billion)
8.3.5.4. Germany T-cell Therapy Market Size And Forecast By Indication, 2022-2032, ($Billion)
8.3.6. France
8.3.6.1. France T-cell Therapy Market Size And Forecast By Modality, 2022-2032, ($Billion)
8.3.6.2. France T-cell Therapy Market Size And Forecast By Therapy Type, 2022-2032, ($Billion)
8.3.6.3. France T-cell Therapy Market Size And Forecast By Therapy Type, 2022-2032, ($Billion)
8.3.7. U.K
8.3.7.1. U.K. T-cell Therapy Market Size And Forecast By Modality, 2022-2032, ($Billion)
8.3.7.2. U.K. T-cell Therapy Market Size And Forecast By Therapy Type, 2022-2032, ($Billion)
8.3.7.3. U.K. T-cell Therapy Market Size And Forecast By Therapy Type, 2022-2032, ($Billion)
8.3.8. Spain
8.3.8.1. Spain T-cell Therapy Market Size And Forecast By Modality, 2022-2032, ($Billion)
8.3.8.2. Spain T-cell Therapy Market Size And Forecast By Therapy Type, 2022-2032, ($Billion)
8.3.8.3. Spain T-cell Therapy Market Size And Forecast By Indication, 2022-2032, ($Billion)
8.3.9. Italy
8.3.9.1. Italy T-cell Therapy Market Size And Forecast By Modality, 2022-2032, ($Billion)
8.3.9.2. Italy T-cell Therapy Market Size And Forecast By Therapy Type, 2022-2032, ($Billion)
8.3.9.3. Italy T-cell Therapy Market Size And Forecast By Indication, 2022-2032, ($Billion)
8.3.10. Russia
8.3.10.1. Russia T-cell Therapy Market Size And Forecast By Modality, 2022-2032, ($Billion)
8.3.10.2. Russia T-cell Therapy Market Size And Forecast By Therapy Type, 2022-2032, ($Billion)
8.3.10.3. Russia T-cell Therapy Market Size And Forecast By Indication, 2022-2032, ($Billion)
8.3.11. Rest of Europe
8.3.11.1. Rest of Europe T-cell Therapy Market Size And Forecast By Modality, 2022-2032, ($Billion)
8.3.11.2. Rest of Europe T-cell Therapy Market Size And Forecast By Therapy Type, 2022-2032, ($Billion)
8.3.11.3. Rest of Europe T-cell Therapy Market Size And Forecast By Indication, 2022-2032, ($Billion)
8.4. Asia-Pacific
8.4.1. Key Market Trends And Opportunities
8.4.2. Asia-Pacific T-cell Therapy Market Size And Forecast By Country, 2022-2032, ($Billion)
8.4.3. Asia-Pacific T-cell Therapy Market Size And Forecast By Modality, 2022-2032, ($Billion)
8.4.4. Asia-Pacific T-cell Therapy Market Size And Forecast By Therapy Type, 2022-2032, ($Billion)
8.4.5. Asia-Pacific T-cell Therapy Market Size And Forecast By Indication, 2022-2032, ($Billion)
8.4.6. China
8.4.6.1. China T-cell Therapy Market Size And Forecast By Modality, 2022-2032, ($Billion)
8.4.6.2. China T-cell Therapy Market Size And Forecast By Therapy Type, 2022-2032, ($Billion)
8.4.6.3. China T-cell Therapy Market Size And Forecast By Indication, 2022-2032, ($Billion)
8.4.7. India
8.4.7.1. India T-cell Therapy Market Size And Forecast By Modality, 2022-2032, ($Billion)
8.4.7.2. India T-cell Therapy Market Size And Forecast By Therapy Type, 2022-2032, ($Billion)
8.4.7.3. India T-cell Therapy Market Size And Forecast By Indication, 2022-2032, ($Billion)
8.4.8. Japan
8.4.8.1. Japan T-cell Therapy Market Size And Forecast By Modality, 2022-2032, ($Billion)
8.4.8.2. Japan T-cell Therapy Market Size And Forecast By Therapy Type, 2022-2032, ($Billion)
8.4.8.3. Japan T-cell Therapy Market Size And Forecast By Indication, 2022-2032, ($Billion)
8.4.9. South Korea
8.4.9.1. South Korea T-cell Therapy Market Size And Forecast By Modality, 2022-2032, ($Billion)
8.4.9.2. South Korea T-cell Therapy Market Size And Forecast By Therapy Type, 2022-2032, ($Billion)
8.4.9.3. South Korea T-cell Therapy Market Size And Forecast By Indication, 2022-2032, ($Billion)
8.4.10. Rest of APAC
8.4.10.1. Rest of APAC T-cell Therapy Market Size And Forecast By Modality, 2022-2032, ($Billion)
8.4.10.2. Rest of APAC T-cell Therapy Market Size And Forecast By Therapy Type, 2022-2032, ($Billion)
8.4.10.3. Rest of APAC T-cell Therapy Market Size And Forecast By Indication, 2022-2032, ($Billion)
8.5. Rest of The World
8.5.1. Key Market Trends And Opportunities
8.5.2. Rest of The World T-cell Therapy Market Size And Forecast By Modality, 2022-2032, ($Billion)
8.5.3. Rest of The World T-cell Therapy Market Size And Forecast By Therapy Type, 2022-2032, ($Billion)
8.5.4. Rest of The World T-cell Therapy Market Size And Forecast By Indication, 2022-2032, ($Billion)
8.5.5. Rest of The World T-cell Therapy Market Size And Forecast By Country, 2022-2032, ($Billion)
8.5.6. Latin America
8.5.6.1. Latin America T-cell Therapy Market Size And Forecast By Modality, 2022-2032, ($Billion)
8.5.6.2. Latin America T-cell Therapy Market Size And Forecast By Therapy Type, 2022-2032, ($Billion)
8.5.6.3. Latin America T-cell Therapy Market Size And Forecast By Indication, 2022-2032, ($Billion)
8.5.7. Middle East
8.5.7.1. Middle East T-cell Therapy Market Size And Forecast By Modality, 2022-2032, ($Billion)
8.5.7.2. Middle East T-cell Therapy Market Size And Forecast By Therapy Type, 2022-2032, ($Billion)
8.5.7.3. Middle East T-cell Therapy Market Size And Forecast By Indication, 2022-2032, ($Billion)
8.5.8. Africa
8.5.8.1. Africa T-cell Therapy Market Size And Forecast By Modality, 2022-2032, ($Billion)
8.5.8.2. Africa T-cell Therapy Market Size And Forecast By Therapy Type, 2022-2032, ($Billion)
8.5.8.3. Africa T-cell Therapy Market Size And Forecast By Indication, 2022-2032, ($Billion)
Chapter 9. Competitive Landscape
9.1. Market Overview
9.2. Market Share Analysis/Key Player Positioning
9.3. Developmental Strategy Benchmarking
9.3.1. New Product Development
9.3.2. Product Launches
9.3.3. Business Expansions
9.3.4. Partnerships, Joint Ventures, And Collaborations
9.3.5. Mergers And Acquisitions
Chapter 10. Company Profiles
10.1. Amgen (US)
10.1.1. Company Snapshot
10.1.2. Financial Performance
10.1.3. Product Offerings
10.1.4. Key Strategic Initiatives
10.1.5. SWOT Analysis
10.2. Bluebird Bio Inc. (US)
10.2.1. Company Snapshot
10.2.2. Financial Performance
10.2.3. Product Offerings
10.2.4. Key Strategic Initiatives
10.2.5. SWOT Analysis
10.3. Fate Therapeutics (US)
10.3.1. Company Snapshot
10.3.2. Financial Performance
10.3.3. Product Offerings
10.3.4. Key Strategic Initiatives
10.3.5. SWOT Analysis
10.4. Gilead Sciences Inc. (US)
10.4.1. Company Snapshot
10.4.2. Financial Performance
10.4.3. Product Offerings
10.4.4. Key Strategic Initiatives
10.4.5. SWOT Analysis
10.5. Merck KGaA (Germany)
10.5.1. Company Snapshot
10.5.2. Financial Performance
10.5.3. Product Offerings
10.5.4. Key Strategic Initiatives
10.5.5. SWOT Analysis
10.6. Novartis AG (Switzerland)
10.6.1. Company Snapshot
10.6.2. Financial Performance
10.6.3. Product Offerings
10.6.4. Key Strategic Initiatives
10.6.5. SWOT Analysis
10.7. Pfizer Inc. (US)
10.7.1. Company Snapshot
10.7.2. Financial Performance
10.7.3. Product Offerings
10.7.4. Key Strategic Initiatives
10.7.5. SWOT Analysis
10.8. Sorrento Therapeutics (US)
10.8.1. Company Snapshot
10.8.2. Financial Performance
10.8.3. Product Offerings
10.8.4. Key Strategic Initiatives
10.8.5. SWOT Analysis
10.9. TCR² Therapeutics (US)
10.9.1. Company Snapshot
10.9.2. Financial Performance
10.9.3. Product Offerings
10.9.4. Key Strategic Initiatives
10.9.5. SWOT Analysis
10.10. TScan Therapeutics, Inc. (US)
10.10.1. Company Snapshot
10.10.2. Financial Performance
10.10.3. Product Offerings
10.10.4. Key Strategic Initiatives
10.10.5. SWOT Analysis
*The List of Company Is Subject To Change During The Final Compilation of The Report
Key Players
- Amgen (US)
- Bluebird Bio Inc. (US)
- Fate Therapeutics (US)
- Gilead Sciences Inc. (US)
- Merck KGaA (Germany)
- Novartis AG (Switzerland)
- Pfizer Inc. (US)
- Sorrento Therapeutics (US)
- TCR² Therapeutics (US)
- TScan Therapeutics, Inc. (US)
Market Segments
By Modality
- Research
- Commercialized
By Therapy Type
- CAR T-cell Therapy
- T-cell Receptor (TCR)-based
- Tumor Infiltrating Lymphocytes (TIL)-based
By Indication
- Hematologic Malignancies
- Solid Tumors
- Others
By Region
- North America
- The U.S.
- Canada
- Mexico
- Europe
- The UK
- Germany
- France
- Spain
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
- Rest of the World
- Latin America
- The Middle East
- Africa